Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exosomes | 5 | 2026 | 126 | 3.690 |
Why?
|
| Cannabidiol | 4 | 2025 | 10 | 3.230 |
Why?
|
| Lung Neoplasms | 7 | 2025 | 495 | 2.860 |
Why?
|
| Cannabinoids | 3 | 2023 | 73 | 2.130 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2025 | 307 | 2.090 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2025 | 347 | 1.960 |
Why?
|
| Milk | 2 | 2026 | 56 | 1.850 |
Why?
|
| Doxorubicin | 4 | 2025 | 97 | 1.800 |
Why?
|
| Drug Carriers | 5 | 2025 | 174 | 1.770 |
Why?
|
| Mice, Nude | 7 | 2025 | 408 | 1.710 |
Why?
|
| Taxoids | 4 | 2017 | 50 | 1.580 |
Why?
|
| Antineoplastic Agents | 7 | 2025 | 1019 | 1.570 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 133 | 1.560 |
Why?
|
| Cell Line, Tumor | 13 | 2025 | 2676 | 1.270 |
Why?
|
| Acrylamides | 3 | 2025 | 14 | 1.270 |
Why?
|
| Aniline Compounds | 3 | 2025 | 28 | 1.260 |
Why?
|
| Drug Delivery Systems | 4 | 2026 | 277 | 1.230 |
Why?
|
| Animals | 22 | 2026 | 16992 | 1.060 |
Why?
|
| Noscapine | 2 | 2017 | 17 | 1.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 220 | 1.000 |
Why?
|
| Mice | 13 | 2026 | 6644 | 0.990 |
Why?
|
| Octreotide | 1 | 2026 | 3 | 0.980 |
Why?
|
| Apoptosis | 6 | 2025 | 1568 | 0.940 |
Why?
|
| Liposomes | 5 | 2021 | 132 | 0.940 |
Why?
|
| Chemistry, Pharmaceutical | 4 | 2020 | 97 | 0.920 |
Why?
|
| Biological Availability | 6 | 2025 | 116 | 0.910 |
Why?
|
| Carboplatin | 1 | 2025 | 20 | 0.910 |
Why?
|
| Cell Survival | 4 | 2024 | 945 | 0.850 |
Why?
|
| Killer Cells, Natural | 1 | 2025 | 104 | 0.840 |
Why?
|
| Organoids | 2 | 2022 | 37 | 0.840 |
Why?
|
| Immunotherapy | 1 | 2025 | 144 | 0.830 |
Why?
|
| Polyethylene Glycols | 3 | 2019 | 108 | 0.790 |
Why?
|
| Administration, Oral | 5 | 2026 | 260 | 0.770 |
Why?
|
| Pharmaceutical Preparations | 2 | 2023 | 94 | 0.770 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 161 | 0.730 |
Why?
|
| Neuralgia | 1 | 2022 | 22 | 0.710 |
Why?
|
| Skin | 1 | 2023 | 187 | 0.710 |
Why?
|
| Nanoparticles | 3 | 2020 | 460 | 0.710 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 112 | 0.690 |
Why?
|
| Cholecalciferol | 2 | 2018 | 20 | 0.680 |
Why?
|
| Thiadiazoles | 1 | 2020 | 6 | 0.680 |
Why?
|
| Spiro Compounds | 1 | 2020 | 16 | 0.670 |
Why?
|
| Lipids | 2 | 2020 | 256 | 0.660 |
Why?
|
| RNA, Small Interfering | 2 | 2025 | 436 | 0.650 |
Why?
|
| Solubility | 4 | 2025 | 139 | 0.640 |
Why?
|
| Tissue Engineering | 1 | 2021 | 75 | 0.640 |
Why?
|
| Humans | 22 | 2025 | 43102 | 0.630 |
Why?
|
| Paclitaxel | 3 | 2025 | 64 | 0.620 |
Why?
|
| Rats | 7 | 2023 | 3735 | 0.620 |
Why?
|
| Valproic Acid | 1 | 2019 | 21 | 0.590 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 224 | 0.590 |
Why?
|
| MicroRNAs | 1 | 2025 | 518 | 0.590 |
Why?
|
| Polymers | 1 | 2020 | 155 | 0.580 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 241 | 0.570 |
Why?
|
| Pyrimidines | 3 | 2025 | 139 | 0.560 |
Why?
|
| Tacrolimus | 1 | 2018 | 16 | 0.560 |
Why?
|
| Tamoxifen | 1 | 2018 | 69 | 0.550 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 47 | 0.550 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 99 | 0.550 |
Why?
|
| Eye Diseases | 1 | 2018 | 29 | 0.540 |
Why?
|
| Phosphofructokinase-2 | 1 | 2017 | 2 | 0.540 |
Why?
|
| Indoles | 3 | 2025 | 187 | 0.540 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 51 | 0.530 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 134 | 0.510 |
Why?
|
| Inflammation | 2 | 2019 | 758 | 0.480 |
Why?
|
| Dioxolanes | 1 | 2015 | 3 | 0.470 |
Why?
|
| Quinazolines | 1 | 2015 | 38 | 0.460 |
Why?
|
| Drug Compounding | 3 | 2020 | 93 | 0.430 |
Why?
|
| Micelles | 3 | 2019 | 36 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 186 | 0.410 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 178 | 0.400 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2019 | 1766 | 0.360 |
Why?
|
| Neoplasms | 1 | 2023 | 1377 | 0.360 |
Why?
|
| Mice, Inbred BALB C | 3 | 2024 | 694 | 0.350 |
Why?
|
| Female | 8 | 2025 | 24698 | 0.300 |
Why?
|
| Eye | 2 | 2021 | 77 | 0.290 |
Why?
|
| Drug Synergism | 3 | 2018 | 195 | 0.290 |
Why?
|
| Thiazoles | 2 | 2019 | 76 | 0.270 |
Why?
|
| Coumarins | 2 | 2019 | 45 | 0.260 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 1723 | 0.250 |
Why?
|
| Proteomics | 2 | 2022 | 378 | 0.250 |
Why?
|
| Particle Size | 2 | 2017 | 272 | 0.250 |
Why?
|
| Equidae | 1 | 2026 | 1 | 0.250 |
Why?
|
| Caco-2 Cells | 2 | 2015 | 64 | 0.230 |
Why?
|
| Dogs | 1 | 2026 | 204 | 0.230 |
Why?
|
| Genetic Engineering | 1 | 2025 | 37 | 0.230 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2026 | 388 | 0.220 |
Why?
|
| Benzophenones | 1 | 2024 | 11 | 0.220 |
Why?
|
| STAT3 Transcription Factor | 1 | 2025 | 102 | 0.220 |
Why?
|
| Computer Simulation | 1 | 2026 | 408 | 0.200 |
Why?
|
| Needles | 1 | 2023 | 10 | 0.200 |
Why?
|
| Ibuprofen | 1 | 2023 | 34 | 0.190 |
Why?
|
| Administration, Cutaneous | 1 | 2023 | 48 | 0.190 |
Why?
|
| Male | 4 | 2026 | 23409 | 0.180 |
Why?
|
| Rodentia | 1 | 2022 | 47 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1455 | 0.180 |
Why?
|
| Monensin | 1 | 2001 | 4 | 0.180 |
Why?
|
| Ricin | 1 | 2001 | 4 | 0.180 |
Why?
|
| Immunotoxins | 1 | 2001 | 13 | 0.180 |
Why?
|
| Microfluidics | 1 | 2021 | 45 | 0.160 |
Why?
|
| Models, Animal | 1 | 2020 | 151 | 0.160 |
Why?
|
| Half-Life | 2 | 2015 | 63 | 0.160 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 152 | 0.160 |
Why?
|
| Drug Stability | 1 | 2020 | 129 | 0.160 |
Why?
|
| Retina | 1 | 2022 | 289 | 0.160 |
Why?
|
| Perfusion | 1 | 2019 | 38 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 306 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 159 | 0.150 |
Why?
|
| Calcium Compounds | 1 | 2019 | 6 | 0.150 |
Why?
|
| Silicates | 1 | 2019 | 3 | 0.150 |
Why?
|
| Rabbits | 1 | 2019 | 278 | 0.150 |
Why?
|
| Cations | 1 | 2019 | 50 | 0.150 |
Why?
|
| Drug Resistance, Multiple | 1 | 2019 | 28 | 0.150 |
Why?
|
| Swine | 1 | 2019 | 212 | 0.150 |
Why?
|
| Mice, SCID | 1 | 2019 | 158 | 0.140 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2018 | 35 | 0.140 |
Why?
|
| X-Ray Diffraction | 1 | 2018 | 66 | 0.140 |
Why?
|
| Benzalkonium Compounds | 1 | 2018 | 2 | 0.140 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2018 | 83 | 0.140 |
Why?
|
| Integrins | 1 | 2018 | 54 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 290 | 0.140 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2017 | 3 | 0.140 |
Why?
|
| Hot Temperature | 1 | 2018 | 141 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 237 | 0.130 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2017 | 34 | 0.130 |
Why?
|
| Kinetics | 1 | 2019 | 695 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2017 | 84 | 0.130 |
Why?
|
| Gene Transfer Techniques | 1 | 2017 | 53 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2017 | 104 | 0.130 |
Why?
|
| Surface Properties | 1 | 2017 | 160 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2021 | 561 | 0.130 |
Why?
|
| Gene Silencing | 1 | 2017 | 154 | 0.130 |
Why?
|
| Caspase 3 | 1 | 2017 | 227 | 0.130 |
Why?
|
| Plasmids | 1 | 2017 | 244 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1869 | 0.120 |
Why?
|
| Cell Migration Assays | 1 | 2016 | 3 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2019 | 536 | 0.120 |
Why?
|
| Phenotype | 1 | 2019 | 780 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 196 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2016 | 107 | 0.120 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 84 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 105 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2017 | 346 | 0.120 |
Why?
|
| Lung | 1 | 2019 | 492 | 0.120 |
Why?
|
| Piperidones | 1 | 2015 | 10 | 0.120 |
Why?
|
| Cyclosporine | 1 | 2015 | 36 | 0.120 |
Why?
|
| Tubulin | 1 | 2016 | 96 | 0.120 |
Why?
|
| Excipients | 1 | 2015 | 25 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2015 | 95 | 0.120 |
Why?
|
| Nanostructures | 1 | 2017 | 161 | 0.120 |
Why?
|
| Microsomes, Liver | 1 | 2015 | 75 | 0.110 |
Why?
|
| Microtubules | 1 | 2016 | 121 | 0.110 |
Why?
|
| Enzyme Activation | 1 | 2016 | 462 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2015 | 368 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2013 | 109 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2016 | 986 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 968 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1596 | 0.090 |
Why?
|
| Cell Movement | 1 | 2016 | 655 | 0.090 |
Why?
|
| HL-60 Cells | 1 | 2001 | 33 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2001 | 159 | 0.040 |
Why?
|